Skip to main content

Table 3 Survival-related characteristics in type II PSOCs underwent SCR

From: The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

Variable Univariate Multivariate
TTP (OR 95%CI) OS (OR 95%CI) TTP (OR 95%CI) OS (OR 95%CI)
FIGO stage
 I-II 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference)
 III-IV 3.55 (1.89–10.05) 4.18 (2.42–11.27) 2.13 (0.93–4.28) 3.24 (0.83–4.28)
 Ascites 1.85 (1.35–2.54) 1.99 (1.38–2.33) 1.54 (1.25–2.06) 1.85 (0.83–2.25)
 Optimal initial CRS 6.33 (2.26–16.08) 6.20 (3.53–15.06) 5.08 (2.45–15.25) 6.12 (3.44–14.67)
 Optimal SCR 4.81 (1.98–13.21) 5.95 (3.45–17.26) 4.68 (1.85–13.48) 6.28 (4.20–16.60)
 NAC 1.12 (0.96–1.49) 1.25 (0.77–2.27) 1.19 (0.94–1.47) 1.25 (0.82–2.21)
 SNAC 1.10 (0.73–1.28) 1.29 (0.80–2.02) 1.05 (0.87–1.35) 1.21 (0.88–1.97)
 PFI 1.08 (1.00–1.15) 1.12 (1.08–1.25) 1.08 (1.00–1.17) 1.12 (1.07–1.26)
 Nadir CA-125 1.01 (1.00–1.03) 1.02 (1.00–1.05) 1.02 (1.00–1.02) 1.03 (1.00–1.05)
  1. TTP time to progression, OS overall survival